What Is Semaglutide?

Semaglutide, brand name Wegovy, is a weekly injectable drug treatment approved by the U.S. Food and Drug Administration to treat severe obesity in adults.

Semaglutide is the generic drug name for Wegovy and Ozempic, which are the name brands.

Tirzepatide is the generic drug name for Mounjaro, which is the name brand.

Semaglutide Injections For Obesity Management

Semaglutide is a weekly injection that has proven effective and safe weight loss treatment. It was approved by the FDA in 2020 for managing excess weight and is considered one of the few prescription-only anti-obesity medications.

The injection works by acting on the GLP-1 receptors, which results in decreased appetite and improved satiety. Clinical trials have shown that weekly doses of semaglutide can result in up to 10 percent weight loss within months, and 19 percent within six months.

For people with diabetes, a dose of semaglutide (2.4mg) a week was found to help prevent glucose control problems associated with type 2 diabetes. It promotes long-term blood sugar control and significant weight loss without causing adverse effects on cardiovascular health or any other complications related to heart health or kidney function.